{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:20:54Z","timestamp":1780082454976,"version":"3.54.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clineuro.2025.109120","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T22:43:01Z","timestamp":1757025781000},"page":"109120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Role for long term treatment in NMOSD induced by the immune checkpoint inhibitor cemiplimab"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2848-7993","authenticated-orcid":false,"given":"Fien","family":"Oelbrandt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2025.109120_bib1","doi-asserted-by":"crossref","DOI":"10.17305\/bjbms.2018.2756","article-title":"The role of the hedgehog signaling pathway in cancer: a comprehensive review","author":"Skoda","year":"2018","journal-title":"Assoc. Basic Med. Sci. FBIH"},{"key":"10.1016\/j.clineuro.2025.109120_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.893063","article-title":"Basal cell carcinoma and hedgehog pathway inhibitors: focus on immune response","author":"Gambini","year":"2022","journal-title":"Front. Media S. A"},{"key":"10.1016\/j.clineuro.2025.109120_bib3","series-title":"A Comprehensive Review of Immune Checkpoint Inhibitors for Cancer Treatment","author":"Arafat Hossain","year":"2024"},{"issue":"2","key":"10.1016\/j.clineuro.2025.109120_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clineuro.2025.109120_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.clineuro.2025.109120_bib6","series-title":"Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review","author":"Marini","year":"2021"},{"key":"10.1016\/j.clineuro.2025.109120_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.803410","article-title":"Incidence and distinct features of immune checkpoint Inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis","volume":"12","author":"Hamada","year":"2021","journal-title":"Front. Immunol."},{"issue":"5_suppl","key":"10.1016\/j.clineuro.2025.109120_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.5_suppl.37","article-title":"Myasthenia gravis and Guillain-Barr\u00e9 syndrome adverse events with immune checkpoint inhibitors","volume":"36","author":"Garcia","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clineuro.2025.109120_bib9","series-title":"Immune-Related Aseptic Meningitis and Strategies to Manage Immune Checkpoint Inhibitor Therapy: A Systematic Review","author":"Nannini","year":"2022"},{"key":"10.1016\/j.clineuro.2025.109120_bib10","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clineuro.2025.109120_bib11","series-title":"Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review","author":"Zammit","year":"2024"},{"key":"10.1016\/j.clineuro.2025.109120_bib12","series-title":"Role of B Cells in Immune-related Adverse Events following Checkpoint Blockade","author":"Dhodapkar","year":"2023"},{"key":"10.1016\/j.clineuro.2025.109120_bib13","series-title":"How We Identify and Treat Neuromuscular Toxicity Induced by Immune Checkpoint Inhibitors","author":"Jordan","year":"2021"},{"key":"10.1016\/j.clineuro.2025.109120_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.msard.2017.12.012","article-title":"Paraneoplastic neuromyelitis optica spectrum disorder: a single center cohort description with two cases of histological validation","volume":"20","author":"Beauchemin","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.clineuro.2025.109120_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2025.109120_bib16","series-title":"Using Combination Therapy to Overcome Diverse Challenges of Immune Checkpoint Inhibitors Treatment","author":"Birnboim-Perach","year":"2024"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725004032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725004032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T12:18:39Z","timestamp":1757074719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846725004032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":16,"alternative-id":["S0303846725004032"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109120","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role for long term treatment in NMOSD induced by the immune checkpoint inhibitor cemiplimab","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109120"}}